InvestorsHub Logo
Followers 137
Posts 22621
Boards Moderated 0
Alias Born 04/08/2004

Re: xodcode post# 212919

Friday, 10/04/2019 9:25:23 AM

Friday, October 04, 2019 9:25:23 AM

Post# of 455314

“This is a remarkable first strong signal for patients with Rett syndrome especially given that the strong effects were seen in adult patients, and we look forward to discussing these results with the FDA and the European regulatory agency as we continue our Rett Syndrome Program including pediatric patients,” said Walter E Kaufmann, MD, Principal Investigator of the study and Chief Medical Officer of Anavex. “Importantly, we’ve now observed that the ANAVEX®2-73 (blarcamesine) effect is correlated with changes of Glutamate and GABA levels, objective measures and biomarkers in several neurodevelopmental disorders.”



https://www.anavex.com/wp-content/uploads/2019/09/ANAVEX2-73-RS-001-Finland-Conference-Sept-2019-Final.pdf

Good luck and GOD bless,
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News